Pulmonary Aspergillosis in Cystic Fibrosis Lung Transplant Recipients

Nunley, David R.; Ohori, N. Paul; Grgurich, Wayne F.; Iacono, Aldo; Williams, Princess A.; Dauber, James H.

doi:10.1378/chest.114.5.1321

Cited by 131 publications

(92 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Invasive aspergillosis, however, occurs in 3 to 15% (ϳ6% on average) of the patients (27,34,40,101,104,121,129,139,144,157,195,198,218,221,293,333,341); 58% of these infections are tracheobronchitis or bronchial anastomotic in-fections, 32% are invasive pulmonary aspergillosis, and 22% are disseminated infections with extrapulmonary involvement (293). Aspergillus infection occurs a median of 3.2 months after transplantation, with 51% occurring within 3 months and 72% occurring within 6 months after transplantation (293).…”

Section: Lung Transplant Recipientsmentioning

confidence: 99%

“…Colonization with Aspergillus is common in patients with cystic fibrosis before transplantation (221,232). While these patients have been shown to be at risk for developing bronchial anastomotic infections, particularly within the first month of transplantation, the risk for pulmonary or disseminated infections does not appear to be higher.…”

Section: Lung Transplant Recipientsmentioning

confidence: 99%

See 1 more Smart Citation

AspergillusInfections in Transplant Recipients

2005

View full text Add to dashboard Cite

Aspergillus infections are occurring with an increasing frequency in transplant recipients. Notable changes in the epidemiologic characteristics of this infection have occurred; these include a change in risk factors and later onset of infection. Management of invasive aspergillosis continues to be challenging, and the mortality rate, despite the use of newer antifungal agents, remains unacceptably high. Performing molecular studies to discern new targets for antifungal activity, identifying signaling pathways that may be amenable to immunologic interventions, assessing combination regimens of antifungal agents or combining antifungal agents with modulation of the host defense mechanisms, and devising diagnostic assays that can rapidly and reliably diagnose infections represent areas for future investigations that may lead to further improvement in outcomes

show abstract

Section: Lung Transplant Recipientsmentioning

confidence: 99%

Section: Lung Transplant Recipientsmentioning

confidence: 99%

AspergillusInfections in Transplant Recipients

2005

View full text Add to dashboard Cite

show abstract

“…The median time to onset of invasive aspergillosis in lung transplant recipients in the current era is 483 days posttransplant (27) infection (33) and pre/postcolonization of the airways with Aspergillus (34)(35)(36). (9).…”

Section: Lung Transplant Recipientsmentioning

confidence: 99%

Invasive Aspergillosis in Solid Organ Transplant Recipients

Singh

Husain

2009

American Journal of Transplantation

113

View full text Add to dashboard Cite

“…Invasive aspergillosis has been described as occurring following up to 18% of heart and lung transplants [23], but mortality can be reduced with pre-emptive therapy and reduced immunosuppression [6,24].…”

Section: Aspergillus Speciesmentioning

confidence: 99%

Fungal infections in transplant recipients

Nicod

Howarth

2001

Eur Respir J

View full text Add to dashboard Cite

Fungi are ubiquitous and the respiratory tract is exposed to aerosolized spores of both fungi that are “pathogenic” even in the normal host, such asCryptococus neoformans, and those that are “opportunistic”, such asCandidaandAspergillusspecies, among others. Although these latter species may occasionally form fungal balls or induce allergic phenomena in the normal host, they produce more invasive diseases in immunosuppressed patients. Among these diseases, pseudomembranous aspergillosis has recently been described.The diagnostic approach to these entities, and, in particular, the thin dividing line between colonization and infection are addressed, along with the diagnostic value of the various procedures.New prophylactic regimens are reviewed such as the possibility of using amphotericin aerosols in combination with systemic azole administration.The authors would emphasize the importance of restoring lung defences by not only decreasing immunosuppressive regimens but also considering the use of newly available recombinant cytokines such as growth factors, to reduce neutropenia, for instance, in addition to antifungal drugs when infection is diagnosed. However, immunomodulation procedures are far from being well established.

show abstract

Pulmonary Aspergillosis in Cystic Fibrosis Lung Transplant Recipients

Cited by 131 publications

References 23 publications

AspergillusInfections in Transplant Recipients

AspergillusInfections in Transplant Recipients

Invasive Aspergillosis in Solid Organ Transplant Recipients

Fungal infections in transplant recipients

Contact Info

Product

Resources

About